معرفی
Professor Gareth Sanger is a leading neuropharmacologist at Queen Mary University of London's Blizard Institute (Faculty of Medicine and Dentistry), renowned for identifying 5-HT3 receptors' role in emesis—revolutionizing anti-emetic cancer therapies—and pioneering human tissue models to study nausea mechanisms and age-related gastrointestinal degeneration.
His educational background includes:
- BSc in Physiology, University of Newcastle-upon-Tyne
- PhD in Physiology, University of Manchester
- Pharmacology Fellowship, King's College Hospital Medical School, London
Sanger's research centers on gastrointestinal neuropharmacology, with emphasis on region-specific neuromuscular changes during ageing and synergistic nauseogenic hormone actions. His lab uses human stomach/colon tissues to model dysregulated motility in nausea and constipation, revealing cholinergic decline in the elderly colon and vasopressin's role in gastric disruption. This work, recognized by NC3R and LUSH for reducing animal testing, bridges molecular mechanisms with clinical applications.
Analysis of his recent publications shows consistent focus on ageing gastrointestinal tract pathophysiology, nauseogenic mechanisms (particularly vasopressin and substance P), and innovative methodologies like stretchable electrophysiology devices. His work spans human tissue validation, cross-species comparisons, and therapeutic development for gastroparesis and chemotherapy-induced complications.
Key honors include:
- Pharmaceutical Research & Manufacturers of America Discoverer's Award
- Sir James Black Award for Contributions to Drug Discovery
- Fellow of the British Pharmacology Society
- Fellow of the Royal Society of Biology
Sanger actively supervises postgraduate researchers (including Marie-Ange Kouassi and Marilisa Straface) and serves as pharmaceutical industry consultant for gastrointestinal drug development. His editorial roles include the British Journal of Pharmacology, and his NC3R-recognized lab collaborates with surgeons and bioengineers to translate findings into clinical solutions for nausea and age-related motility disorders.
His laboratory within the Centre for Neuroscience, Surgery and Trauma develops human tissue models for gastrointestinal drug testing, with ongoing projects exploring long-term gastric function models for gastroparesis and neurogenesis potential in enteric glial cells.
